Deciphera Pharmaceuticals has been granted a patent for a method of treating c-KIT-mediated cancers, including GIST, using a combination of a specific compound and MAPKAP kinase inhibitors. This innovative approach shows promise in the treatment of tumors with c-KIT mutations. GlobalData’s report on Deciphera Pharmaceuticals gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
According to GlobalData’s company profile on Deciphera Pharmaceuticals, Cancer treatment biomarkers was a key innovation area identified from patents. Deciphera Pharmaceuticals's grant share as of May 2024 was 28%. Grant share is based on the ratio of number of grants to total number of patents.
Treatment of c-kit-mediated cancers, including gist, using specific inhibitors
A recently granted patent (Publication Number: US11986463B2) discloses a method for treating tumors with c-KIT mutations, specifically gastrointestinal stromal tumors (GIST), in patients. The method involves administering a combination of 1-[4-bromo-5-[1-ethyl-7-(methylamino)-2-oxo-1,2-dihydro-1,6-naphthyridin-3-yl]-2-fluorophenyl1-3-phenylurea or its salt, along with MAPKAP kinase inhibitors like trametinib, binimetinib, cobimetinib, or ulixertinib.
The patent claims cover various aspects of the treatment method, including the specific c-KIT mutations targeted (primary mutations in exon 9, 11, 13, or 17, and secondary resistance mutations in exon 13, 14, 17, or 18), the nature of mutations (deletion or substitution), and the history of resistance to previous treatments like imatinib, sunitinib, or regorafenib. Additionally, the method extends to treating various types of tumors beyond GIST, such as lung adenocarcinoma, squamous cell lung cancer, glioblastoma, pediatric glioma, astrocytoma, sarcoma, and melanoma. This patent provides a comprehensive approach to treating tumors with specific genetic mutations, offering a potential breakthrough in personalized medicine for cancer patients.
To know more about GlobalData’s detailed insights on Deciphera Pharmaceuticals, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies
